Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Lubiprostone in Combination With Standard PEG Preparation
NCT00689026 · Augusta University · NA · terminated · last registry update 2014-10-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Augusta University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CLCN2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-06-25Phase 3 first posted: Braintree Laboratories, BLI400 Laxative + Lubiprostone (NCT02481947)
- 2014-05-14Phase 3 first posted: Sucampo Pharma Americas, LLC, Lubiprostone (NCT02138136)
- 2014-02-11Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT00380250)
- 2014-01-22Phase 3 first posted: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT02042183)
- 2013-11-25Phase 3 first posted: Mallinckrodt, Lubiprostone + Placebo (NCT01993875)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision